

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4669955
<b>Application Number:</b>	10698099
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7805
<b>Title of Invention:</b>	Prevention and treatment of synucleinopathic disease
<b>First Named Inventor/Applicant Name:</b>	Dale B. Schenk
<b>Customer Number:</b>	20350
<b>Filer:</b>	Rosemarie L. Celli/Tina Trieu
<b>Filer Authorized By:</b>	Rosemarie L. Celli
<b>Attorney Docket Number:</b>	015270-008930US
<b>Receipt Date:</b>	23-JAN-2009
<b>Filing Date:</b>	31-OCT-2003
<b>Time Stamp:</b>	19:47:14
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	227-WO0160794A2.pdf	2087535 <small>11986c6df938c1a57264ff1055b766cd6677</small>	no	55

**Warnings:**

**Information:**

2	Foreign Reference	228-WO0160794A3.pdf	142902 e0b07c6d687b49c5e63412c3d3b5513a554928	no	3
<b>Warnings:</b>					
<b>Information:</b>					
3	Foreign Reference	220-WO03045128A2.pdf	8086079 a57ac2f8b09da7c6b188c5b700494cd4c5f56d80	no	265
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	221-WO03045128A3.pdf	288170 780137b10102bf65d6462879cc5f192162ce55721	no	6
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	235-WO03000714A2.pdf	601845 a8ee56c717923eeed8b0d001138413e38cf00941	no	12
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	236-WO03000714A3.pdf	126176 c18fdeb00eb581bbee679a0dcfed7a01b0ef3871	no	2
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	222-WO08103472A2.pdf	6759680 2f5d709b7bd721253d8941cc6d8b08f5d7ab9a7	no	135
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	226-AndersonJBC281-40-29739_2006.pdf	2205701 0d090114d527e6e798b1cc9b9c554bc52fcc97dc	no	14
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	240-AlvesDaCosta_.pdf	677046 f137383c69a641b2a8c0c28b1b1b1e05959da1c	no	8
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	224-CHILCOTE_ComparisonofalphasynucleinAbstract.pdf	73698 ee61e01302f8f0813c18d6d210f385d033a6d01	no	2
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	241- Casadesus_TheEstrogenMyth_2006.pdf	513347 541b0e47dc98513e0c952118c0a6d1d9f853e	no	8
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	83-ClelandIsomerization.pdf	711697 a171294b2946dc38d4d6ba796514b97c5de78945	no	7
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	87- Demattos_peripheralantibody_2001.pdf	1402878 #e4bb606eaa14712efc2041c73aee0598487a792	no	6
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	237- EP037830083-3_EuroSupplSearch.pdf	407998 417b4208b627042c182995650597b61e00915e	no	11
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	238- EP05814041-9_SupplEuroSearchReport.pdf	1237320 e8849903b0dc91da6c62b0ce98d22ef001a007	no	26
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	104- FRIEDLAND_MOLNEUROLOGY_1994.pdf	584220 e0290b275c72c341f067465983769813bd2983df	no	7
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	242- JanewayTravers_IMMUNObio_1997.pdf	918196 01d6d71e9949b675d23bd6de9d052e02585240e	no	5
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	229- Hashimoto_BetaSynucleinInhibitsAlpha.PDF	575287 31da919172e053d2bde42ac18c18c0a078ba0c99b03	no	6
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	233- Heiser_InhibitionHuntingtinFibrillogenesis_2000.PDF	381220 1c48b97a6f1214c0baa02c04187a74221973e44	no	3
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	232- Lecerf_HumanSingleChainFV_2001.PDF	326703 07186c3d9994e13638a0ba26a7ab759f8f	no	3
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	126-Lee_HumanAlphaSyn.pdf	677836 5a2b840/d579946f6d5f470e74d208993c0b	no	6
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	225- Lee_TruncatedAlphaAbstract.pdf	32849 58bae0b73d19c3dc9f16c9dfeebdc572bc84b1	no	2
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	243- Perrin_EpitopeMapping_Absract.pdf	444367 2b01fa07fcb499c0c75f2bbdbdc04523aa35c8	no	4
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	234- Rochet_Inhibitionoffibrillization_2000.PDF	453068 9a154f2c3a925c078b6e6a8c0f6027c1f8f408	no	4
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	244- Sidhu_DoesAlphaSynuclein_2004.pdf	1199334 3d1f8bd11e24aa63d91a72a799af9d799b8ff465c	no	11
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	245- Spillantini_AlphaSynucleinInLewyBodies_1997.pdf	240936 d18b7e6ddc4d8c14c56c0be1dc745e0e087c1780	no	2
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	246- Takeda_AbnormalAccum_1998.pdf	428192 ca18a2120c0a04629a0f5c2d9f1e6da7a07e	no	6
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	247- Tofaris_PhysiologicalProperties.pdf	729672 413c0f6e23847a7e0ca7104718130a09929629	no	8
<b>Warnings:</b>					
<b>Information:</b>					

29	NPL Documents	223- TofarisJBC278-45-44405_2003. pdf	343038  b1b4a6a04c1d3dc711b62186217abb4c5e ec2d4	no	7
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	231- Wanker_ProtienAggregationin HuntingtonsandParkinsonsDis. 2000.PDF	360972  31ee8faa1c5162a50017c0ee742b0174d a1dc6	no	3
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	230- Windsch_DevelopmentOfAne wTreatment_2002.PDF	324397  18b4ff3ab14f0ee51776c4d15d88a1ed42 b14	no	4
<b>Warnings:</b>					
<b>Information:</b>					
32		015270-008930US_SIDS_to247 _2009-01-23.PDF	300501  230b0591113b726e03e48157d4db421018 ee98b	yes	7
<b>Multipart Description/PDF files in .zip description</b>					
		<b>Document Description</b>	<b>Start</b>	<b>End</b>	
		Information Disclosure Statement Letter	1	3	
		Information Disclosure Statement (IDS) Filed (SB/08)	4	7	
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			33642860		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					